Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Carbogen Buys French Finished-Dosage Firm

by Rick Mullin
January 23, 2012 | A version of this story appeared in Volume 90, Issue 4

Carbogen Amcis, a Swiss pharmaceutical chemical firm, has acquired Creapharm Parenterals, a division of France’s Creapharm involved in the contract manufacture of finished-dose drugs. The deal will allow Carbogen to provide customers with services “from process development to the supply of pharmaceutical substances and formulated products,” says CEO Mark Griffiths. Fine chemicals makers such as Cambrex and Albany Molecular Research Inc. also have added drug formulation capabilities to their service offerings.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.